Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
9,775$
-1,06%
Echtzeit-Aktienkurs Stoke Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Stoke Therapeutics Inc. Aktie
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
…
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.…
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday - Altimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR)
…
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
…
Stoke Therapeutics STK-001: A Potential Game-Changer For Dravet Syndrome
…
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
…
Stoke Therapeutics prices upsized equity offering of $125M
…
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.…
Stoke Therapeutics Inc. surges following impressive study data By Investing.com
Stoke Therapeutics Inc. surges following impressive study data…
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do…
Stoke therapeutics CFO sells over $25k in company stock By Investing.com
Stoke therapeutics CFO sells over $25k in company stock…
Stoke Therapeutics executive sells over $25k in company stock By Investing.com
Stoke Therapeutics executive sells over $25k in company stock…